Wall Street brokerages expect Novavax, Inc. (NASDAQ:NVAX) to post earnings per share of ($0.15) for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Novavax’s earnings, with the lowest EPS estimate coming in at ($0.16) and the highest estimate coming in at ($0.14). Novavax posted earnings per share of ($0.21) in the same quarter last year, which would suggest a positive year over year growth rate of 28.6%. The company is scheduled to report its next quarterly earnings report on Monday, February 26th.
According to Zacks, analysts expect that Novavax will report full year earnings of ($0.62) per share for the current financial year, with EPS estimates ranging from ($0.65) to ($0.60). For the next year, analysts anticipate that the firm will report earnings of ($0.60) per share, with EPS estimates ranging from ($0.83) to ($0.50). Zacks’ EPS calculations are an average based on a survey of research firms that that provide coverage for Novavax.
Several equities analysts recently commented on NVAX shares. Citigroup raised shares of Novavax from a “neutral” rating to a “buy” rating and set a $2.00 price objective for the company in a research note on Tuesday, October 31st. Zacks Investment Research cut shares of Novavax from a “hold” rating to a “sell” rating in a research note on Thursday, November 16th. BidaskClub raised shares of Novavax from a “hold” rating to a “buy” rating in a research note on Saturday, December 30th. S&P Equity Research reduced their price objective on shares of Novavax from $1.81 to $1.35 in a research note on Wednesday, January 10th. Finally, Cantor Fitzgerald reaffirmed a “hold” rating and set a $2.00 price objective on shares of Novavax in a research note on Wednesday, November 8th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and three have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $2.64.
Novavax (NASDAQ:NVAX) opened at $2.03 on Thursday. The company has a market cap of $636.64, a P/E ratio of -2.99 and a beta of 2.68. Novavax has a 12 month low of $0.73 and a 12 month high of $2.32. The company has a debt-to-equity ratio of -4.28, a quick ratio of 3.31 and a current ratio of 3.31.
TRADEMARK VIOLATION WARNING: “-$0.15 Earnings Per Share Expected for Novavax, Inc. (NVAX) This Quarter” was published by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international trademark and copyright law. The original version of this piece of content can be read at https://www.americanbankingnews.com/2018/02/15/0-15-earnings-per-share-expected-for-novavax-inc-nvax-this-quarter.html.
Novavax Company Profile
Novavax, Inc is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.